A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
Recruiting
Observational Study
Locally Advanced Unresectable or Metastatic Gastric Cancer
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 610 (estimated)
- Sponsor
- Akeso · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
2. Subjects have received prior systemic therapy in sponsor-initiated clinical trials of cadonili…
Contacts